FDA lays out cancer PRO strategy

FDA staff set out the agency’s thinking and progress in developing a standard approach to assessing patient reported outcomes (PROs) at a workshop Friday to discuss clinical outcome assessments in cancer trials. The joint FDA-American Society of Clinical Oncology

Read the full 399 word article

User Sign In